Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224360 · ClinicalTrials.gov registry record · Phase 2
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
A Phase 2 study of Sickle Cell Disease, sponsored by CSL Behring.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 3
- Study locations
NCT07224360 is a Phase 2 study of Sickle Cell Disease that is actively recruiting participants, run by CSL Behring. The registered enrollment target is 63 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07224360, a Phase 2 study of Sickle Cell Disease, is actively recruiting participants, sponsored by CSL Behring.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 weeks at the MTD in the maintenance period.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Anumigilimab
Study Locations (3)
Florida
- The Foundation for Sickle Cell Disease - Hollywood
Mississippi
- Southern Specialty Research - Flowood
New York
- Jacobi Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2026-02-02 |
| Est. Completion | 2028-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224360
The ClinicalTrials.gov registry entry for NCT07224360 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (78% lower). The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07224360 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Mississippi, New York.
Frequently Asked Questions
What is clinical trial NCT07224360 about?
NCT07224360 is a clinical study titled "Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)". This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigili...
What is the current status of trial NCT07224360?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2026-02-02. Estimated completion is 2028-06-29.
What conditions does trial NCT07224360 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT07224360?
The interventions under investigation include: Placebo (DRUG), Anumigilimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT07224360?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224360 being conducted?
This trial has 3 study locations across Florida, Mississippi, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.